APOM and obesity due to melanocortin 4 receptor deficiency: Other studies demonstrated that circulating ApoM levels are significantly lower in individuals with obesity, metabolic syndrome, type 2 diabetes and gestational diabetes compared to lean, non-diabetic controls.